Potential Therapeutic Targets for PTPN2-Linked Disorders (G5771)

Target Name: PTPN2

NCBI ID: G5771

PTPN2

Potential Therapeutic Targets for PTPN2-Linked Disorders

Protein tyrosine phosphatase non-receptor type 2 (PTPN2) is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the phosphatidylinositol (PI) signaling pathway, which is involved in various cellular processes including cell signaling, protein synthesis, and cell survival. Mutations in the PTPN2 gene have been linked to various neurological and psychiatric disorders, making it an attractive drug target for researchers.

The PTPN2 gene is located on chromosome 11q22 and encodes a protein with 194 amino acid residues. The protein has a catalytic core with four conserved acid residues at its C-terminus, which are involved in its catalytic activity. Additionally, PTPN2 has a N-terminus that is highly conserved and is involved in its ability to interact with other proteins.

PTPN2 is a critical enzyme in the PI signaling pathway, as it adds a phosphate group to the phosphorylated target protein. This phosphorylation is important for the regulation of various cellular processes, including cell signaling, protein synthesis, and cell survival. The PI signaling pathway is a highly conserved pathway that is involved in many cellular processes, including cell signaling, cell survival, and protein synthesis. The PTPN2 enzyme plays a key role in the regulation of this pathway by adding a phosphate group to its target proteins.

Mutations in the PTPN2 gene have been linked to various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. These mutations have been shown to disrupt the normal function of the PTPN2 enzyme and result in the production of misfolded or aggregated proteins that can cause harmful effects in the brain. Therefore, targeting PTPN2 with drugs or other therapeutic approaches is a promising strategy for the treatment of these disorders.

PTPN2 has also been shown to be a potential biomarker for various neurological and psychiatric disorders. The misfolded or aggregated proteins produced by mutations in the PTPN2 gene can be detected in brain tissue or blood samples using various techniques, such as Western blotting or immunofluorescence. These proteins can then be used as probes to study the localization and distribution of the misfolded or aggregated proteins in the brain. This approach has the potential to diagnose and monitor the progression of various neurological and psychiatric disorders.

In conclusion, PTPN2 is a protein that plays a critical role in the regulation of the PI signaling pathway and has been linked to various neurological and psychiatric disorders. The development of drugs or other therapeutic approaches that target PTPN2 is a promising strategy for the treatment of these disorders. Additionally, PTPN2 has the potential to serve as a biomarker for the diagnosis and monitoring of these disorders. Further research is needed to fully understand the role of PTPN2 in the regulation of the PI signaling pathway and its potential as a drug target or biomarker.

Protein Name: Protein Tyrosine Phosphatase Non-receptor Type 2

Functions: Non-receptor type tyrosine-specific phosphatase that dephosphorylates receptor protein tyrosine kinases including INSR, EGFR, CSF1R, PDGFR. Also dephosphorylates non-receptor protein tyrosine kinases like JAK1, JAK2, JAK3, Src family kinases, STAT1, STAT3 and STAT6 either in the nucleus or the cytoplasm. Negatively regulates numerous signaling pathways and biological processes like hematopoiesis, inflammatory response, cell proliferation and differentiation, and glucose homeostasis. Plays a multifaceted and important role in the development of the immune system. Functions in T-cell receptor signaling through dephosphorylation of FYN and LCK to control T-cells differentiation and activation. Dephosphorylates CSF1R, negatively regulating its downstream signaling and macrophage differentiation. Negatively regulates cytokine (IL2/interleukin-2 and interferon)-mediated signaling through dephosphorylation of the cytoplasmic kinases JAK1, JAK3 and their substrate STAT1, that propagate signaling downstream of the cytokine receptors. Also regulates the IL6/interleukin-6 and IL4/interleukin-4 cytokine signaling through dephosphorylation of STAT3 and STAT6 respectively. In addition to the immune system, it is involved in anchorage-dependent, negative regulation of EGF-stimulated cell growth. Activated by the integrin ITGA1/ITGB1, it dephosphorylates EGFR and negatively regulates EGF signaling. Dephosphorylates PDGFRB and negatively regulates platelet-derived growth factor receptor-beta signaling pathway and therefore cell proliferation. Negatively regulates tumor necrosis factor-mediated signaling downstream via MAPK through SRC dephosphorylation. May also regulate the hepatocyte growth factor receptor signaling pathway through dephosphorylation of the hepatocyte growth factor receptor MET. Also plays an important role in glucose homeostasis. For instance, negatively regulates the insulin receptor signaling pathway through the dephosphorylation of INSR and control gluconeogenesis and liver glucose production through negative regulation of the IL6 signaling pathways. May also bind DNA

The "PTPN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PTPN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets